This platform is currently in private beta. All information is subject to change at any time and should be confirmed with your rep or Majestic contact. Available by invitation only — do not share your link or password. All information is confidential and intended solely for the named recipient.
Nothing on this platform constitutes medical advice, a solicitation, or an offer to sell securities. For practitioner and qualified investor use only.
Compounded Semaglutide, Tirzepatide, and Retatrutide — sourced from our South Carolina manufacturing partner, tested by independent labs, and shipped directly to your practice. From decision to first patient in 20 days.
More peptides expanding to catalog Q3–Q4 2026 · Pricing subject to volume
Most peptide suppliers source overseas and won't show you their facility. We manufacture in South Carolina, test with independent labs, and welcome you to visit in person — because "trust us" is not a quality standard.
All compounds manufactured and packaged at our partner facility in South Carolina — not repackaged from overseas API. Lab visits available and encouraged.
Every lot tested by TrustPointe Analytics LLC (Dorr, MI) or Chromate before it ships. COAs confirm identity, purity, and quantity — QR codes and access keys link directly to the issuing lab's verification portal.
You don't build a peptide program alone. Every starter package includes training, documentation, and 90 days of Metis analytics — all included at no extra cost.
Three compounds covering the full metabolic spectrum — from the most-prescribed GLP-1 therapy, to a dual GIP/GLP-1 agonist, to the next generation of triple agonists. More peptides added to catalog Q3–Q4 2026.
| Compound | Classification | Vial Size | Price / Vial | Price / mg | Patient Pricing Range | Key Clinical Use |
|---|---|---|---|---|---|---|
|
Semaglutide
Pro Peptide Solutions, SC
|
GLP-1 | 30 mg | $262.50 | $8.75 | $60–$80/mo | Weight management, T2D glycemic control |
|
Tirzepatide
Pro Peptide Solutions, SC
|
DUAL AGONIST | 200 mg | $750.00 | $3.75 | $200–$300/mo | Dual GIP/GLP-1 agonism, superior weight outcomes |
|
Retatrutide
Pro Peptide Solutions, SC
⚠ Investigational — Not FDA-Approved
|
TRIPLE AGONIST | 60 mg | $525.00 | $8.75 | $350–$450/mo | Triple agonist (GIP/GLP-1/glucagon), next-gen metabolic Research/investigational use only. Not FDA-approved. |
Retatrutide Disclosure: Retatrutide is an investigational compound currently in Phase 3 clinical trials. It has not received FDA approval for any indication. It is offered for research and investigational use only. Practitioners assume full responsibility for appropriate use in compliance with applicable regulations.
Whether you're new to peptides or looking to add a better supplier, the program is designed to close the gap between your first conversation and your first paying patient in 20 days.
15 minutes with your Majestic R&D representative. We'll review the program, discuss your patient population, and confirm the program is right for your practice.
Your rep forwards your patient count data to Metis. Within days, you receive a personalized profit projection — conservative, base case, and accelerated — based on your actual patient population.
Fill out expected patient volume per compound. The calculator shows your monthly burn rate and time to exhaust a $30,000 inventory. Target: 12 months or less.
One-page application. 10–15 minutes. Credit decision in approximately 1 week. No collateral, no personal credit check. $30,000 at 10% APR fixed over 5 years — ~$650/month.
Upon funding approval, Majestic places your order with Pro Peptide Solutions. Pro Peptide ships with COA documentation. Delivered to your practice within 5–7 business days.
Two 2-hour remote sessions with Christopher McDonald. Documentation toolkit delivered. Metis 90-day Dashboard activated. Begin treating patients and generating revenue that offsets your $650/month from day one.
90-day milestone: 10–30 patients treated, workflow documented, reorder cadence established, 3 Metis action items implemented. Revenue exceeds $650/month payment from target patient volumes.
We provide ~$650 in peptide inventory monthly that you resell for ~$1,300 — more than covering your payment. The program effectively finances itself from the first reorder cycle.
At target patient volumes, revenue exceeds the monthly financing payment from day one. Year-one projections assume a standard 503A compounding partner relationship with typical cash-pay pricing architecture. The $60K figure represents entry-level volume — the minimum threshold for program qualification. Your Metis Profit Snapshot will project your specific practice at conservative, base, and accelerated scenarios.
Profit Snapshot included: Metis generates a personalized revenue projection based on your actual patient counts — conservative, base case, and accelerated — before you commit.
Enter your expected patient volume for each compound. The calculator shows your monthly revenue, profit, and how long a $30,000 order will last — so you can confirm the program fits your practice before making any commitment.
How the math works:Patient pricing is set at 2× your cost — a standard cash-pay margin. You control your exact pricing. These are conservative estimates based on typical practice pricing architecture.
Projections assume 2× patient pricing markup. Actual results vary by practice pricing, patient adherence, and compound mix. This calculator is for estimation purposes only.
Everything below is verifiable. We've built the program so you never have to take our word for anything.
TrustPointe Analytics LLC or Chromate. COA confirms identity, purity, and quantity. QR code and access key link directly to the lab’s own verification portal — not to us.
Pro Peptide Solutions, South Carolina. Lab visits are available to any practitioner or investor who wants to see production in person. We encourage it.
Informed consent templates, lot tracking logs, adverse event forms, reconstitution cards, EMR guidance. Ready to use before your first patient.
Metis builds your Profit Snapshot — a full revenue projection based on your actual patient counts — before you commit to anything. No pressure, just numbers.
All pricing published upfront. No hidden fees, no surprise reorder costs. Volume pricing available — ask your rep.
These are real lot numbers from our active inventory. Click any link to verify purity and identity directly at the issuing laboratory’s portal. No login required.
Lot numbers and verification keys update with each new inventory order. Current lots reflect active physician inventory.
Every Majestic practitioner receives a complimentary 90-day Metis Peptide Sprint Dashboard — a custom analytics and optimization platform built specifically for your practice, activated the moment you commit to the program.
Delivered before you commit. Metis builds a custom revenue projection using your patient count data — including conservative, base case, and accelerated scenarios.
A customized interactive portal activated upon your inventory order. Your practice through data — for the first time.
A structured worksheet and EHR query protocol to identify your first 15–25 peptide candidates. Most practices find 40–80 candidates from chart review alone.
You don't operate in a vacuum. Metis provides benchmark data from the Majestic practitioner network — pricing intelligence, ramp comparisons, and the top performer playbook.
Metis services provided by Kevin Dixon — metisconsulting.ai | peptide@metisconsulting.com
The 90-day Sprint Dashboard is complimentary and exclusive to Majestic R&D practitioners. No additional purchase required.
Pro Peptide Solutions, South Carolina. Lab visits available and encouraged. We don’t ask you to trust us — we show you.
Every lot tested by TrustPointe Analytics LLC (Dorr, MI) or Chromate. COAs confirm identity, purity (99.75–99.85%), and quantity. Verify any lot directly at TrustPointeLIMS.com or chromate.org/verify using the key on your COA.
Informed consent templates, lot tracking logs, adverse event forms, reconstitution cards, and EMR documentation guidance — all included with your starter package.
"Most suppliers source overseas and won't let you see their facilities. We manufacture in the USA and welcome lab visits — because 'trust us' is not enough."— MAJESTIC R&D PROGRAM STANDARD
The GLP physician program is Phase 1. The Majestic R&D peptide division is building toward expanded delivery modalities and a broader compound library.
Investigational program exploring intranasal routes for peptide administration — targeting CNS bioavailability, patient compliance advantages over injection-based protocols, and application to CNS-active peptide candidates beyond GLP compounds.
Housed under Majestic R&D core research. Leverages LFDS ThermosPore/PsychroPore platform technology.
Pulmonary delivery of peptides via ultrasonic nebulizer systems. Investigates bioavailability, particle size compatibility with LFDS micellar formulations, and patient-friendly alternatives to subcutaneous injection for appropriate compound classes.
Compatible with LFDS encapsulation platform. Research partnership pathways open.
Addition of healing, recovery, and hormonal peptide classes to the physician offering — including BPC-157 analogs, TB-500 class compounds, sermorelin/ipamorelin family, and PT-141 type candidates. Manufacturing partner already capable.
Timeline: Q3–Q4 2026. Physician partners will receive priority access.
Reach out to your Majestic R&D representative directly, or fill out the form and we'll get back to you within one business day. No commitment required to receive your Profit Snapshot.
Intro call, free practice analysis, lab visit, or just a question — tell us what you need.
This section contains confidential investment materials including the full Capital Expenditure & Scenario Analysis, manufacturing buildout projections, and investment structure. Access requires a password.
To receive access credentials, contact Preet Patel at majesticrdinfo@gmail.com.
Peptide Manufacturing Buildout · Capital Expenditure Analysis · April 2026 · UMBC Facility / Aurora Manufacturing Program
Why manufacturing is the moat — and why now is the moment to build it.
The GLP peptide market is the fastest-growing segment in compounded pharmaceuticals. Demand is outpacing supply infrastructure. Current distribution relies almost entirely on overseas-sourced API — a structural vulnerability that creates both a quality gap and a regulatory risk for practitioners.
Majestic R&D is building the domestic manufacturing capability that closes this gap — and the physician program already underway creates the anchor client demand that makes the buildout economics unambiguous.
The physician program is live. 12 practitioner conversations initiated in under 3 weeks, with 3 practices in the sample stage. Once the first physicians close, the anchor client commitment is met — and manufacturing investment becomes a compounding asset rather than a speculative one.
We are not asking investors to bet on the market. We are asking them to fund the infrastructure to serve demand that already exists and is growing monthly.
Seed round to fund Scenario 1 buildout. Numbers firm once first physician closes.
Both scenarios use the UMBC facility via the Aurora manufacturing program. Both hit anchor client demand by Month 7.
| Metric | Scenario 1 — 50 kg/mo | Scenario 2 — 100 kg/mo |
|---|---|---|
| Total Investment | $3,440,000 | $10,400,000 |
| Build Timeline | 10 months | 18 months |
| Revenue Starts (Anchor Client) | Month 7 | Month 7 |
| Monthly Revenue at Steady State | $7,500,000 | $15,000,000 |
| Monthly Gross Profit | $5,415,000 | $11,000,000 |
| Gross Margin | 72% | 73% |
| CapEx Payback Period | < 1 month at full production | < 1 month at full production |
| Market Position | Defensible | Dominant |
| Expansion Platform | Add Scenario 2 from profits | 200, 300+ kg/mo ready |
Month-by-month from funding to steady-state production at 50 kg/month.
| Period | Phase / Milestones | Production | Revenue Potential | Spend / OpEx |
|---|---|---|---|---|
| Months 1–2 | Equipment acquisition, facility upgrades, team onboarding | 0 kg | $0 | $400K–$700K |
| Month 3 | Process development begins, first peptide synthesis campaigns | 1 kg | $0 | $300K |
| Month 4 | Second peptide synthesis campaign | 1 kg | $0 | $350K |
| Month 5 | Purification and analytical qualification begins | 2 kg | $300K | $300K |
| Month 6 | Scale-up testing, batch analytics intensive | 4 kg | $750K | $300K |
| Month 7 ★ | Anchor client commitment met — 27 kg/month target reached | 27 kg | $4,050,000 | $250K |
| Month 8 | Yield optimization and QC release cadence established | 35 kg | $5,250,000 | $200K |
| Month 9 | Ramp continues, external sales capacity available | 42 kg | $6,300,000 | $100K |
| Month 10+ | Full steady-state — 50 kg/month | 72% gross margin | 50 kg/mo | $7,500,000/mo | $85K/mo OpEx |
Total: $3,440,000. Analytics and batch quality constitute the largest technical risk-reduction block.
Both scenarios produce ~72–73% gross margin. Both break even in under one month of production relative to distributor pricing. The only variable is scale and market capture speed.
GLP demand is at an all-time high and growing. Domestic manufacturing capacity is severely constrained. Every month without US-based infrastructure is market share left to overseas suppliers with inferior quality controls.
At 100 kg/month, Majestic would supply a significant portion of the US compounding market. This position cannot be easily replicated — regulatory, technical, and capital barriers to entry are substantial and growing.
The physician program creates anchor client demand before the first manufacturing dollar is spent. Scenario 1 payback period is under one month at steady state — the capital risk window is narrow and bounded.
"Scenario 1 is the lower-risk entry point that fulfills the anchor client commitment, proves the manufacturing model, and generates positive cash flow by Month 8. Profits from Scenario 1 can fund a Scenario 2 expansion without additional dilution."
— MAJESTIC R&D CAPEX ANALYSIS · APRIL 2026
For investment inquiries, term sheet requests, and due diligence access.
This document is confidential and intended solely for authorized recipients. All figures are projections based on Aurora manufacturing program estimates and current market pricing. Actual results may vary. This does not constitute an offer of securities.